[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Definium Therapeutics US, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641561","phase-3-a-phase-3-trial-of-dt120-for-major-depressive-disorder-ascend-100641561",false,"NCT07592689","A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend","Inclusion Criteria:\n\n1. Diagnosis of MDD per DSM-5\n2. Male or female aged 18 to 74\n3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration\n4. MADRS Total Score ≥26\n5. CGI-S Score ≥4\n\nExclusion Criteria:\n\n1. Certain psychiatric disorders (other than major depressive disorder)\n2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder\n3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine\n4. Any clinically significant unstable illness","ALL","18 Years","74 Years",{"count":20,"type":21},165,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend",[27],"Major Depressive Disorder","RECRUITING","2026-06-26",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2026-05-10",{"date":36,"type":21},"2028-06",{"name":38,"class":39},"Definium Therapeutics US, Inc.","INDUSTRY",27,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100616307","phase-2-a-phase-2a-trial-of-dt402-for-autism-spectrum-disorder-100616307","NCT07303907","A Phase 2A Trial of DT402 for Autism Spectrum Disorder","An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder","Inclusion Criteria:\n\n1. Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)\n2. Male or Female aged 18 to 65\n3. Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66\n\nExclusion Criteria:\n\n1. Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking\n2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder\n3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)\n4. Any clinically significant unstable illness","65 Years",{"count":50,"type":21},20,[52],"PHASE2","A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder",[55,56],"Autism Spectrum Disorder","ASD","2026-03-31",{"date":59,"type":32},"2026-04-06",{"date":61,"type":32},"2025-12-03",{"date":63,"type":21},"2027-08",{"name":38,"class":39},1,""]